Want to see BDX full AI Analyst Report?
Revenue by Segment
Breaks down sales by business unit (for example, medical devices, medication management, and diagnostic systems), showing which segments drive growth, how segment mix impacts profitability and cash flow, and where management is focusing investment or restructuring efforts.BD’s revenue mix is shifting: Interventional and Medical are the steady growth engines, while new reporting lines (Biopharma Systems, Connected Care, Medical Essentials) appearing in late‑2025/early‑2026 reflect a reporting reorg and a strategic pivot toward biologics and advanced patient monitoring. Management says Biopharma is now ~55% biologics and APM, PureWick and tissue regeneration delivered double‑digit growth, underpinning organic momentum. Near‑term risks—Alaris upgrade‑cycle comparisons, weak vaccine demand, China softness, tariffs and an FDA ship‑hold—could pressure H2 results, but strong cash flow, buybacks, BD Excellence productivity and a raised EPS guide support margin resilience and investor returns.
Date | Other | Life Sciences | Medical | Interventional | Medical Essentials | Connected Care | Biopharma Systems |
|---|---|---|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $0.00 | $0.00 | $1.41B | $1.68B | $1.22B | $670.00M |
Mar 31, 2026 | $0.00 | $0.00 | $0.00 | $1.36B | $1.65B | $1.12B | $590.00M |
Dec 31, 2025 | $0.00 | $766.00M | $0.00 | $1.33B | $1.59B | $1.13B | $429.00M |
Sep 30, 2025 | $0.00 | $1.37B | $3.15B | $1.37B | $0.00 | $0.00 | $0.00 |
Jun 30, 2025 | $0.00 | $1.25B | $2.93B | $1.33B | $0.00 | $0.00 | $0.00 |
Mar 31, 2025 | $0.00 | $1.25B | $2.76B | $1.26B | $0.00 | $0.00 | $0.00 |
Dec 31, 2024 | $0.00 | $1.30B | $2.62B | $1.26B | $0.00 | $0.00 | $0.00 |
Sep 30, 2024 | $0.00 | $1.34B | $2.84B | $1.26B | $0.00 | $0.00 | $0.00 |
Jun 30, 2024 | -$67.00M | $1.26B | $2.56B | $1.24B | $0.00 | $0.00 | $0.00 |
Mar 31, 2024 | $0.00 | $1.30B | $2.45B | $1.29B | $0.00 | $0.00 | $0.00 |